| Assessment Status | Rapid Review Complete |
| HTA ID | 20039 |
| Drug | Atezolizumab |
| Brand | Tecentriq® |
| Indication | Atezolizumab monotherapy is indicated as treatment of locally advanced or metastatic urothelial carcinoma (LaMUC) in adult patients who are considered cisplatin-ineligible and whose tumours have PD-L1 expression ≥5%. |
| Assessment Process | |
| Rapid review commissioned | 17/08/2020 |
| Rapid review completed | 23/09/2020 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
The HSE has approved reimbursement following confidential price negotiations July 2021.
